Medigene AG (ETR:MDG1 – Get Free Report) was down 8.7% during mid-day trading on Wednesday . The stock traded as low as €0.17 ($0.19) and last traded at €0.19 ($0.22). Approximately 63,357 shares traded hands during trading, a decline of 79% from the average daily volume of 306,207 shares. The stock had previously closed at €0.21 ($0.24).
Medigene Stock Performance
The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.95. The firm has a market capitalization of $1.45 million, a PE ratio of -0.32, a P/E/G ratio of 7.12 and a beta of 0.84. The business has a 50 day moving average price of €1.24 and a 200-day moving average price of €1.41.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Read More
- Five stocks we like better than Medigene
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- Canada Bond Market Holiday: How to Invest and Trade
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- Expert Stock Trading Psychology Tips
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
